| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer (NCT03091842) | University of Southern California | 2019-07-29 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NCT03723928) | SWOG Cancer Research Network | 2018-09-17 |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer (NCT03377101) | National Cancer Institute (NCI) | 2018-08-07 |
| Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors (NCT03523195) | Fred Hutchinson Cancer Center | 2018-04-18 |
| Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03359954) | M.D. Anderson Cancer Center | 2017-11-16 |
| Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (NCT03070002) | Northwestern University | 2017-10-19 |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer (NCT03042897) | University of Southern California | 2017-09-08 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (NCT03128619) | Jonsson Comprehensive Cancer Center | 2017-08-02 |
| Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (NCT03132467) | M.D. Anderson Cancer Center | 2017-06-13 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773) | National Cancer Institute (NCI) | 2016-05-04 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (NCT02648477) | City of Hope Medical Center | 2016-03-28 |
| Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery (NCT02526498) | Rutgers, The State University of New Jersey | 2015-07-15 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (NCT02457910) | Vanderbilt-Ingram Cancer Center | 2015-06-01 |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT02219789) | Mayo Clinic | 2014-12-05 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (NCT02152943) | M.D. Anderson Cancer Center | 2014-07-17 |
| Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery (NCT01754519) | Roswell Park Cancer Institute | 2013-05-01 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (NCT01750073) | University of Nebraska | 2012-12-07 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer (NCT01319539) | National Cancer Institute (NCI) | 2011-04-01 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (NCT01275677) | National Cancer Institute (NCI) | 2011-02-08 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen (NCT00118157) | National Cancer Institute (NCI) | 2005-05-01 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (NCT00338728) | M.D. Anderson Cancer Center | 2003-10-03 |